Discover open access scientific publications

Search, annotate, share and cite publications

Publications by George Tharakan

[18F]Fluciclatide PET as a Biomarker of Response to Combination Therapy of Pazopanib and Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer

European Journal of Nuclear Medicine and Molecular Imaging

English

The Muduga and Kurumba of Kerala, South India and the Social Organization of Hunting and Gathering

Journal of Ecological Anthropology

2007

English

Related publications

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

English

Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

British Journal of Cancer

Cancer Research

Oncology

2003

English

Pcn333 - Real-World Treatment Patterns of Patients With Advanced (Stage Ii-Iv) Ovarian Cancer Classified as Resistant or Refractory to Frontline Platinum-Based Therapy

English

Pcn384 - Health-Related Quality of Life in Patients With Advanced (Stage Ii-Iv) Ovarian Cancer Resistant or Refractory to Frontline Platinum-Based Therapy

English

Multicenter Reproducibility of 18f-Fluciclatide PET Imaging in Subjects With Solid Tumors

Journal of Nuclear Medicine

English

Emodin Sensitizes Paclitaxel-Resistant Human Ovarian Cancer Cells to Paclitaxel-Induced Apoptosis in Vitro

English

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology

English

A Phase I/Ii Study of GLIF Combination Chemotherapy for Taxane/Platinum-Refractory/Resistant Endometrial Cancer (GOGO-EM2)

Cancer Chemotherapy and Pharmacology

English

Pharmacokinetics of Paclitaxel and Metabolites in a Randomized Comparative Study in Platinum-Pretreated Ovarian Cancer Patients.

Journal of Clinical Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by George Tharakan

[18F]Fluciclatide PET as a Biomarker of Response to Combination Therapy of Pazopanib and Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer

The Muduga and Kurumba of Kerala, South India and the Social Organization of Hunting and Gathering

Related publications

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

Pcn333 - Real-World Treatment Patterns of Patients With Advanced (Stage Ii-Iv) Ovarian Cancer Classified as Resistant or Refractory to Frontline Platinum-Based Therapy

Pcn384 - Health-Related Quality of Life in Patients With Advanced (Stage Ii-Iv) Ovarian Cancer Resistant or Refractory to Frontline Platinum-Based Therapy

Multicenter Reproducibility of 18f-Fluciclatide PET Imaging in Subjects With Solid Tumors

Emodin Sensitizes Paclitaxel-Resistant Human Ovarian Cancer Cells to Paclitaxel-Induced Apoptosis in Vitro

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

A Phase I/Ii Study of GLIF Combination Chemotherapy for Taxane/Platinum-Refractory/Resistant Endometrial Cancer (GOGO-EM2)

Pharmacokinetics of Paclitaxel and Metabolites in a Randomized Comparative Study in Platinum-Pretreated Ovarian Cancer Patients.